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A remarkable pathological difference between grey matter lesions (GML) and white matter lesions (WML) in
Multiple Sclerosis (MS) patients is the paucity of infiltrating leukocytes in GML. To better understand these
pathological differences, we hypothesize that the chemokine monocyte chemotactic protein-1 (MCP-1 or CCL2), of
importance for leukocyte migration, and its receptor CCR2 are more abundantly expressed in WML than in GML of
MS patients. To this end, we analyzed CCL2 and CCR2 expression in the hippocampus, comprising WML and GML,
of post-mortem MS patients, and of control subjects.
CCL2 and CCR2 mRNA were significantly increased in demyelinated MS hippocampus. Semi-quantification of CCL2
and CCR2 immunoreactivity showed that CCL2 is present in astrocytes only in active WML. CCR2 is upregulated in
monocytes/macrophages or amoeboid microglia in active WML, and in ramified microglia in active GML, although
to a lesser extent. As a follow-up, we observed a significantly increased CCL2 production by WM-, but not GM-derived
astrocytes upon stimulation with bz-ATP in vitro. Finally, upon CCL2 stimulation, GM-derived microglia significantly
increased their proliferation rate.
We conclude that within hippocampal lesions, CCL2 expression is mainly restricted to WML, whereas the receptor
CCR2 is upregulated in both WML and GML. The relative absence of CCL2 in GML may explain the lack of infiltrating
immune cells in this type of lesions. We propose that the divergent expression of CCL2 and CCR2 in WML and GML
explains or contributes to the differences in WML and GML formation in MS.
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Multiple sclerosis (MS) is a chronic neuroinflammatory
and degenerative disease affecting mostly young adults
in the prime of their life. Clinical features are extremely
varied and include cognitive deficits, e.g. memory impair-
ment [1]. Pathologically, MS is characterized by areas of
focal demyelination which are spread throughout the
entire central nervous system [1]. These demyelinated
lesions can be found in several white matter (WM) as
well as grey matter (GM) areas, ranging from subcortical* Correspondence: amw.vandam@vumc.nl
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unless otherwise stated.and subventricular WM, and tracts within the spinal cord
[2-4] and of the brainstem [2] to GM structures such as
the thalamus [5,6], hypothalamus [7], hippocampus [8,9],
cerebellum [5,10] and cortex [5,6,11].
White matter lesions (WML) are characterized by the
infiltration of large numbers of leukocytes [12-14], which
are considered to play a crucial role in the formation of
WML [15-17]. Although the presence of these cells has
been described in GM lesions (GML) biopsy material of
MS patients [18,19], a range of studies using post-mortem
MS material demonstrated the relative absence of infil-
trated immune cells in GML [11,20-22]. This difference
in immune cell infiltration between post-mortem WML
and GML is best illustrated by leukocortical lesions which
encompass both WM and GM (type I lesions), with mored. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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glia present in the WM than GM part of the lesions [20].
Various hypotheses have been put forward to explain
the apparent pathological differences between WML and
GML, including a putative role for a divergent expression
of chemo-attractant molecules important for the influx of
immune cells into the brain. One such molecule is the
chemokine monocyte-chemotactic protein-1 (MCP-1, also
known as CCL2), which is reported to contribute to the
pathogenesis of MS [23,24], through its involvement in
the migration of leukocytes into the CNS [25-27]. In
addition, CCL2 has been shown to induce migration
[28,29], proliferation [30] and activation [30,31] of micro-
glia in vitro. CCL2 mediates its effects by binding to and
activating the chemokine receptor CCR2. CCL2-CCR2
interaction is essential to evoke the clinical and histo-
pathological characteristics of experimental autoimmune
encephalomyelitis (EAE), an animal model of MS, by
regulating the infiltration of immune cells [26] and activa-
tion of microglial cells [32]. During EAE, a higher number
of infiltrated immune cells correlated with increased dis-
ease severity [33] and blockade of CCL2-CCR2 signaling
ameliorated progression of EAE together with a decrease
in the number of infiltrating immune cells [34]. In post-
mortem human MS tissue, CCL2 expressing astrocytes
have been described to be present in WML [35-37] which
may then contribute to the attraction of immune cells into
WM leading to WML formation.
Based on the described histopathological differences
between WML and GML, we hypothesize that CCL2
and its receptor CCR2 are more abundantly expressed in
WML than in GML of MS patients. To this end, we studied
post-mortem human hippocampus, a brain region known
to be affected during MS, and to contain WML, GML, and
mixed WML and GML [8,9]. We analyzed CCL2 and
CCR2 expression in the hippocampus of MS patients and
control subjects using semi-quantitative qPCR analysis and
immunohistochemistry. An in vitro approach was used to
study bz-ATP-induced CCL2 production by astrocytes
derived from WM versus GM rat brain. Finally, we deter-
mined in vitro whether the CCR2 present in GM-derived
microglia is functionally active, i.e. involved in CCL2
induced proliferation of microglial cells.
Materials and methods
Human subjects
For semi-quantitative qPCR analysis, post-mortem hip-
pocampal tissue was collected as part of the “tissue pro-
curement program” approved by the Cleveland clinic
Institutional Review Board. Hippocampal fresh frozen
tissue of 10 MS patients (age range: 40-73 years) and 5
control subjects (age range: 52-77 years) was included in
this study and pathologically characterized previously
[38]. Clinicopathological data of the MS patients andnon-neurological controls used for qPCR are provided
in Table 1.
For immunohistochemistry, post-mortem human hippo-
campal tissue was obtained from the Netherlands Brain
Bank (NBB, Amsterdam, The Netherlands) or from the
Department of Pathology (VU University Medical Center
in Amsterdam, The Netherlands). Formalin-fixed, paraffin-
embedded hippocampal tissue sections were included from
18 clinically diagnosed and neuropathologically verified MS
patients (age range: 43-77 years) and 9 control subjects (age
range: 50-92 years) without neurological or psychiatric
disease. Clinicopathological data of the MS patients and
non-neurological controls used for immunohistochemistry
are provided in Table 2.
qPCR analysis on human hippocampus material
Fresh hippocampal tissue was homogenized in Qiazol and
total RNA was isolated as described by the manufacturer
using the RNeasy Microarray tissue kit (Qiagen Inc,
Valencia, USA). RNA concentration was determined
spectrophotometrically at 260 nm using the NanoDrop
2000 spectrophotometer (Thermo Fisher Scientific,
Waltham, USA) and purity of the RNA samples was
determined by measuring the absorbance ratio at 260/
230 nm (samples were excluded when ratio was outside
the 2.00-2.20 range) and 260/280 nm (samples were
excluded when ratio was outside the 1.90.-2.10 range).
When RNA quality was approved, 1 μg of RNA was
reverse transcribed into cDNA and the PCR reaction
was carried out using RT2 First Strand kit (Qiagen Inc,
Valencia, USA) according to the manufacturer’s ins-
tructions. For the qPCR reaction, qPCR assays (CCL2:
PPH00192E; CCR2:PPH00612F) were purchased (Qiagen
Inc, Valencia, USA). All reactions were normalized to the
reference gene glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) using the qPCR Assay (PPH00150E, Qiagen
Inc.), which have been found to produce reproducible
results using RT-PCR analysis previously performed
using control and MS hippocampus tissues [38,39].
Amplification of cDNA was performed in MicroAmp
Optical 96-well Reaction Plates (Applied Biosystems Inc,
NY, USA) and the analysis was done using an ABI Biosys-
tems 7300 RT-PCR System (Applied Biosystems Inc, NY,
USA). The 25 μl reaction mixture was composed of RT2
SYBR Green Rox Master Mix (Qiagen Inc.), 1 μl cDNA
and 1 μl of the forward and reverse primers each. As a
negative control, no template (no cDNA) reactions were
performed to exclude DNA contamination, and to confirm
the absence of primer-dimer artifacts from amplification
plots. The reaction conditions were an initial 10 min at
95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at
60°C each. All samples were run in triplicate and mRNA
levels were normalized to the levels of the reference gene
GAPDH using previously published methods [38,39].
Table 1 Clinicopathological data MS patients and control subjects (qPCR study)
Case Gender Age PMD (h) DD MS Type Demyelination COD
MS
1 F 58 7.3 13 RR no Abdominal Adenocarcinoma
2 F 54 5.9 37 SP no Unknown Infection
3 M 63 4.9 36 PP no Sepsis
4 F 54 7.1 5 SP no Drug Overdose
5 F 51 7.0 15 PP no Attempted Suicide (asphyxiation)
6 F 73 7.0 46 PP yes Dehydration/Gastroenteritis
7 F 46 5.6 14 SP yes Unknown
8 M 52 6.7 30 SP yes Pulmonary Infections
9 F 40 5.4 13 SP yes Pneumonia
10 F 66 13.0 35 SP yes Unknown
Control
1 M 65 8.5 Cardiac arrest
2 F 53 36.0 Cardiac thrombosis
3 F 52 12.0 Polymicrobial sepsis
4 M 53 12.0 Myocardial infarct
5 M 77 12.0 Mesenteric bleeding
PMD = Postmortem delay; DD = Disease duration; COD = Cause of death; SP = Secondary progressive; PP = Primary progressive.
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After rapid autopsy (mean postmortem delay: 7.5 h)
hippocampal tissue samples were fixed in 10% formalin
for 30 days and embedded in paraffin. Of 32 paraffin-
embedded tissue blocks, 5-μm sections were cut and
mounted on positively charged glass slides (Menzel-Glaser
SuperFrost plus, Braunschweig, Germany), and dried
overnight at 37°C. Upon use, sections were heated in an
incubator for 30 min at 56°C, before they were deparaf-
finized in xylene, and rehydrated through a series of
100%, 96%, and 70% ethanol and distilled water. For
subsequent antigen retrieval, sections were rinsed in
0.01 M citrate buffer (pH 6.0) or in 10 mM Tris buffer
(pH 9.0) containing 1 mM EDTA (Tris-EDTA) and
subsequently heated in a steamer for 30 min at 90-99°C
in the same buffers. After antigen retrieval, the sections
were allowed to regain room temperature (RT), rinsed
in Tris-buffered saline (TBS), and incubated for 20 min
in TBS containing 0.3% H2O2 and 0.1% sodiumazide.
Non-specific binding sites were blocked with 5% non-
fat dried milk (Campina) in TBS containing 0.5% Triton
(TBS-T; blocking solution) for 30 min at RT. Subse-
quently, sections were incubated overnight at 4°C with
the following primary antibodies: myelin basic protein
(MBP), MHC-II (LN3), CCL2 or CCR2 (see Table 3 for
details on primary antibodies), diluted in blocking solution.
The next day, sections were washed in TBS and incubated
for 2 h at RT in corresponding biotinylated IgG’s (1:400,
Jackson Immunoresearch, Westgrove, PA, USA; see Table 3for details on secondary antibodies), followed by HRP-
labeled avidin-biotin complex (ABC complex 1:400; Vector
Laboratories, Burlingame, CA, USA) for 1 h at RT. To
detect CCL2 immunoreactivity, an amplification step was
included at this stage, and thus sections were subsequently
incubated in biotinylated tyramide (1:800, kindly provided
by Dr. I. Huitinga, Netherlands Institute for Neuroscience,
Amsterdam) and 0.01% peroxide in TBS-T for 30 min,
followed by another incubation with ABC complex (1:800)
in TBS-T for 1 h. Detection of all antigens was visualized
using 3,3-diaminobenzidine (DAB, Sigma, St. Louis, MO,
USA) as a chromogen and counterstaining was performed
with hematoxylin. After dehydration in graded ethanol
solutions, the sections were cleared in xylene and cover-
slipped in Entellan (Merck, Darmstadt, Germany). Negative
controls were performed by omitting the primary anti-
body resulting in no immunohistochemical signal (data
not shown).Immunofluorescent double labeling
Based on the morphological appearance of CCL2 and
CCR2 positive cells, double-labeling of astrocytes and
CCL2 or of microglia and CCR2 was performed. To that
end, antibodies for astrocytes, i.e. glial fibrillary acidic
protein (GFAP), and for CCL2 or antibodies for micro-
glia, i.e. ionized calcium-binding adapter molecule 1 (Iba-1)
and for CCR2 were used. In addition, a double labeling
of CCR2 and the cell proliferation marker BM28 [40]
was performed.
Table 2 Clinicopathological data MS patients and control subjects (immunohistochemistochemical study)
Case Gender Age PMD (h) DD MS Type Demyelination (lesion type) COD
MS
11 M 43 8:30 17 SP yes (active) Pneumonia
12 F 66 6:00 23 SP yes (active) Unknown
13 F 60 10:40 7 PP yes (active) Euthanasia
14 M 54 8:15 12 PP yes (active) Euthanasia
15 F 50 7:35 17 SP yes (active) Euthanasia
16 F 62 6:45 25 Unknown yes (inactive) Unknown
17 M 63 7:05 28 SP yes (inactive) Cardiac arrest after rupture of abdominal aorta
18 M 47 7:15 7 SP yes (inactive) Urosepsis with organ failure
19 M 49 8:00 26 PP yes (inactive) Pneumonia by MS
20 M 66 7:30 26 PP yes (inactive) Ileus
21 M 61 9:15 31 SP yes (inactive) Euthanasia
22 F 57 8:40 27 Unknown yes (inactive) Respiratory insufficiency by (uro)sepsis
23 F 77 5:43 6 Unknown no Respiratory insufficiency with aspiration pneumonia
24 M 71 7:00 26 PP no Pneumonia by aspiration
25 F 76 9:45 20 PP no Unknown
26 M 50 9:30 24 PP no Unknown
27 M 51 11:00 20 Unknown no Unknown
28 M 56 9:50 14 PP no Cachexia and exhaustion by end stage MS
Control
6 M 84 7:05 Exacerbation of COPD
7 M 56 9:15 Myocardial infarction
8 F 62 7:55 Euthanasia
9 F 92 7:00 Acute death, probably pulmonary embolism
10 F 50 4:10 Metastasized large cell bronchocarcinoma
11 F 62 7:20 Metastases
12 M 82 5:10 Pneumonia/cardiovascular accidents
13 M 78 Unknown Cardiac arrest after rupture of abdominal aorta
14 F 84 6:55 Myelodysplasia
PMD = Postmortem delay; DD = Disease duration; COD = Cause of death; SP = Secondary progressive; PP = Primary progressive.
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BM28) with the appropriate primary antibodies. To pre-
vent steric hindrance of the CCL2 antibody and GFAP
antibody, sections were sequentially incubated (GFAP/
CCL2) with the appropriate primary antibodies (see
Table 3 for details on primary antibodies used).Table 3 Primary and secondary antibodies used for single lab
Antigen Antigen retrieval Species Final dilution Source prim
antibody
Human MBP Tris-EDTA Mouse 1:100 Boehringer,
Human MHC-II Citrate Mouse 1:100 Gift, Clone L
Human CCL2 Citrate Mouse 1:200 R&D System
Human CCR2 Citrate Rabbit 1:1000 Abcam, ab3Sections were deparaffinized and antigen retrieval was
performed with citrate or Tris-EDTA buffer as described
above. Non-specific binding sites were blocked with 3%
bovine serum almunin (BSA) (Sigma) in TBS-T for
30 min at RT. All antibodies were diluted in 3% BSA in





1118099 Biotinylated donkey-anti-mouse IgG Jackson, 715-065-151
N3 Biotinylated donkey-anti-mouse IgG Jackson, 715-065-151
s, MAB2791 Biotinylated goat-anti-mouse IgG Jackson, 115-065-146
2144 Biotinylated goat-anti-rabbit IgG Jackson, 111-065-144
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RT with appropriate Alexa Fluor 488 or Alexa Fluor
594 labeled IgG’s (1:400; Molecular Probes) or with
streptavidin-labeled Alexa Fluor 488 (1:400, Molecular
Probes) when the secondary antibodies were biotinyl-
ated (see Table 4 for detailed information on secondary
antibodies and conjugates). After washing, the sections
were coverslipped with Vectashield (Vector Laboratories,
Burlingame, CA, USA). Sections were examined using a
confocal laser scanning microscope (Leica TSC-SP2-
AOBS; Leica Microsystem, Wetzlar, Germany).
Definition of lesion center and border
Lesions were identified by the loss of myelin basic pro-
tein (MBP) immunoreactivity. The border of a lesion is
represented by the edge of demyelinated and myelinated
WM or GM. The center of a lesion is the demyelinating
or demyelinated area between the borders of a WML or
a GML (Figure 1A, F). A distinction was made between
demyelinated WM and GM regions within the hippo-
campus, in which the WM regions comprise the stratum
radiatum and the alveus and GM regions comprise the
cornu ammonis (CA) 1, CA2, CA3 and CA4. The activity
status was determined by the presence or absence of
MHC-II positive monocytes/macrophages or microglia
in the border or center of a lesion. Active/chronic active
and inactive WML were defined as described before
[41,42], in which active and chronic active lesions show
amoeboid monocytes/macrophages in the center (Figure 1B)
or at the border (Figure 1C) of the lesions, respectively,
while inactive lesions are almost devoid of activated im-
mune cells, but do show ramified microglia (Figure 1G, H)
[41-43]. The activity status of GML, which are virtually
devoid of immune cells, was determined by the presence
or absence of MHC-II positive amoeboid macrophages
present within neighboring demyelinated WM which was
part of the same lesion (combined WML and GML) and
the presence of MHC-II positive microglia in the GML.
Although not officially identified as such, we called these









Iba-1 Tris-EDTA Goat 1:300 Abcam, ab5076 Alexa Fluor
donkey anti
GFAP Citrate Rabbit 1:4000 DAKO, Z0334 Alexa Fluor
donkey anti




CCR2 Tris-EDTA Rabbit 1:1000 Abcam, ab32144 Alexa Fluor
donkey anti
BM28 Tris-EDTA Mouse 1:600 BD Transduction
Laboratories, 610700
Biotinylated
anti mousepositive microglia were present, we called these inactive
GML (Figure 1I, J). Thus, to be able to carefully localize
the CCL2 and CCR2 expressing cells, we discriminated
between the center and the borders of WML and GML as
well as between active/chronic active and inactive lesions.
Semi-quantitative analysis of CCL2- and CCR2-positive cells
Semi-quantification of CCL2- and CCR2-positive cell num-
bers was performed by unbiased manually counting the
number of positive cells with a clearly visible cell nucleus
within the region of interest (ROI). In MS lesions, ROIs
were positioned at the white matter border, grey matter
border, white matter lesion center and grey matter lesion
center. The CA4 region was excluded from analysis since
this region often showed nonspecific astrocytic staining
regardless of the presence of lesions. In control subjects
and MS patients without hippocampal lesion, ROIs were
placed in hippocampal WM and GM. In each ROI, cells
were counted in 2 fields, each measuring 0.1-0.4 mm2.
Results were expressed as number of cells (mean and
standard error of the mean) per mm2. All pictures were
acquired using an Olympus-VANOX-T microscope
(Tokyo, Japan) at 10-fold magnification. Cell counting
and area determination were performed using Cell^F
Olympus Soft Imaging Software (Tokyo, Japan).
Primary culture of astrocytes and microglia
Primary astrocytes and microglia were isolated from 1 day
old Wistar rats (Harlan CPB, Zeist, The Netherlands) as
described previously [44] and which was approved by the
Animal Experiment Committee of the VU University
Medical Center, Amsterdam, The Netherlands (approval
ID: FGA 11-03). Mixed glial cells were isolated and
cultured from pons and cerebral cortices to obtain
mainly WM and GM primary astrocytes, respectively.
These brain regions were cleared from adhering men-
inges and blood vessels, and mechanically dissociated
in Dulbecco’s modified Eagle’s medium (DMEM)-F10
(Gibco, Life Technologies, Breda, The Netherlands),

































Figure 1 Histopathological features of active and inactive hippocampal MS lesions. MS lesions are recognized by the loss of MBP immunoreactivity
in hippocampal WM and/or GM areas (A,F). Active and inactive lesions were distinguished based on the presence or absence of MHC-II positive
monocytes/macrophages, respectively. WM within the lesion centre (B) and at the border (C) of the active lesion presents with activated amoeboid
MHC-II positive cells. The number of MHC-II positive cells in the lesion centre (D) and at the border of a GML (E) is far lower compared to WML.
Moreover, LN3+ cells within the GM have a more ramified morphology. LN3+ cells within an inactive lesion are lower in number compared to
active lesions and have a ramified morphology, both within the centre (G) and at the border (H) of WM, as well as in the centre (I) and at the
border of (J) GM. Frames in A & F refer to hippocampal areas shown in B-E; G-J. The dashed lines indicate the border between WM (alveus and
striatum) and GM (CA1). AV = alveus; Str = Striatum. Scale bar (A, F) = 500 μm. Scale bar (B-E; G-J) = 60 μm.
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50 Units/ml penicillin (Sigma-Aldrich) and 50 μg/ml
streptomycin (Gibco). Cells were plated in poly-L-lysine
(15 μg/ml (2 μg/cm2); Sigma-Aldrich) coated T75 culture
flasks (Nunc, Hamstrop, Denmark) and incubated at 37°C
in humidified air containing 5% CO2. The medium was
changed at day 1, day 6 and day 8 after seeding. After
10 days in culture, microglia and astrocytes were sepa-
rated by shaking the flasks at 37°C at 260 rpm for 16 h.
Cortical microglia were directly plated into poly-L-lysine
coated 8-well chamber-slides (Lab-Tek). Astrocytes were
further purified by treatment with 5 mM leucine methyl
ester (LME, Sigma- Aldrich) in serum free medium, for
24 h at 37°C. Subsequently, cortical and pons-derived
astrocytes were plated in poly-L-lysine coated 6-well
plates (Thermo Scientific) containing fresh medium with
serum. Purity of astrocyte cultures was between 80-90% as
determined by immunofluorescent staining using anti-
GFAP antibody (1:6000; DAKO; Z0334). Purity of primary
microglia cultures was between 90-94% as determined
by immunofluorescent staining using anti-Iba1 antibody
(1:1000;WAKO Chemicals USA; 019-19741).Bz-ATP-induced CCL2 expression in white and grey matter
derived astrocytes
To determine the level of CCL2 expression by white and
grey matter derived astrocytes, 0.5 x 106 cells were
plated onto poly-L-lysine coated wells for 24 h at 37°C.
Astrocytes were cultured in serum-free medium alone
(control) or in the presence of Benzoyl-benzoyl adenosine
5’-triphosphate (bz-ATP) (500 μM) for 2 to 6 h (n = 3
independent experiments). Bz-ATP is a potent analogue
of ATP and was chosen as a stimulus because ATP
release is a physiological response upon axonal damage
[45], such as observed in WML and GML in MS [20,42].
Subsequently, ATP (and bz-ATP) acts on purinergic recep-
tors, e.g. P2X7, present on astrocytes [46] resulting in
various responses, including CCL2 production [47]. After
incubation with bz-ATP, astrocytes were homogenized in
Trizol reagent (Life Technologies, Carlsbad, USA) and total
RNA was isolated as described by the manufacturer. RNA
concentration was determined spectrophotometrically at
260 nm using the NanoDrop ND-1000 spectrophotometer
(Thermo Fisher scientific, Waltham, USA) and purity was
determined by measuring the absorbance ratio at 260/
280 nm, and was approved when values were between
1.9 and 2.1. When quality criteria were met, 1 μg of
RNA was reverse transcribed into cDNA using the High
Capacity cDNA Reverse Transcription Kit (Invitrogen)
according to the manufacturer’s instructions, but using
oligo-d(T)16 primers (Applied Biosystems). For the qPCR
reaction, primers for CCL2 (GenBank accession number:
NM_031530.1) and GAPDH (GenBank accession number:NM_017008.3) were designed and purchased from Euro-
gentec (Seraing, Belgium).
GAPDH was identified as the most stable reference gene
compared to four other reference genes, i.e. hypoxanthine
phosphoribosyltransferase 1 (HPRT1), phosphoglycerate
kinase 1 (PGK1), peptidylprolyl isomerase A (cyclophilin or
PPIA) and tyrosine 3-monooxygenase/tryptophan 5- mono-
oxygenase activation protein, zeta polypeptide (YWHAZ).
Details of the primer sequences are as follows:
CCL2 forward primer: 5′-
ACGTGCTGTCTCAGCCAGATG-3′
CCL2 reverse primer: 5′-
GACTCATTGGGATCATCTTGCC-3′
GAPDH forward primer: 5′-
GAACATCATCCCTGCATCCA-3′
GAPDH reverse primer: 5′-
GCCAGTGAGCTTCCCGTTCA-3′
Amplification of cDNA was performed in MicroAmp
Optical 96-well Reaction Plates (Applied Biosystems) and
the analysis carried out using a StepOnePlus Real-Time-
PCR System (Applied Biosystems). The 20 μl reaction
mixture was composed of Power SYBR Green PCR Master
Mix (Applied Biosystems), 12.5 ng cDNA and 4 pM of the
forward and reverse primers each. As a negative control, no
template (no cDNA) reactions were performed. The reac-
tion conditions were an initial 2 min at 50°C, followed by
10 min at 95°C and 40 cycles of 15 sec at 95°C and 1 min
at 60°C. The mRNA expression levels were quantified rela-
tively to the level of the reference gene glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) using the following
calculation: 2-(Cq of target mRNA - Cq of GAPDH) × 100%.
Bromodeoxyuridine labelling assay
In contrast to hippocampal WM, hardly any CCL2 is
present in hippocampal GM as observed in the present
study (see Results section). We thus questioned whether
the CCR2 receptor on GM-derived microglia is activated
by CCL2 and results in a functional response. To this end,
the effect of CCL2 treatment on GM microglia proliferation
was studied. Cortical primary rat microglia were plated on
poly-L-lysine coated chamberslides (2 × 104 cells/chamber)
and allowed to adhere for 2 h. Then, medium was refreshed
and 10 nM of INCB3344 (MedChem Express, Princeton,
USA), a specific CCR2 antagonist [48,49] or vehicle
(medium) together with 20 μM bromodeoxyuridine (BrdU;
Sigma) were added. After 30 min, 50 ng/ml of recombinant
rat MCP-1 (CCL2; Peprotech) was added (n = 3 independ-
ent experiments). After 48 h, the cells were washed and
subsequently fixed with 4% PFA for 20 min, and again
washed three times with 1% Triton X-100 (Sigma-Aldrich)
in PBS. Then, the fixed cells were incubated with 5 units/
100 μl DNAse (Promega, H6101) for 45 min at 37°C.
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goat serum in PBS/1% Triton X-100 for 1 h. To identify
BrdU incorporation, microglia were incubated with rat
anti-BrdU (1:200; Abcam; AB6326) in PBS/1% Triton X-
100 for 24 h at RT, washed with PBS/1% Triton X-100
followed by incubation with Alexa Fluor-488 labeled goat
anti-rat IgG’s (1:200; Molecular Probes) for 2 h at RT.
Cells were washed three times with PBS/1% Triton X-100
and once with PBS, treated for 5 min with 5 μg/ml propi-
diumiodide (PI) and again washed two times with PBS.
Then, the slides were embedded in Vectashield (Vector
Laboratories). Immunofluorescent staining was visualized
using an Olympus VANOX-T microscope (Tokyo, Japan).
In five random 20 × fields per well, the percentage of pro-
liferative cells was calculated as follows: (number of BrdU
positive cells/ number of PI positive nuclei) × 100%.
Statistics
Statistical analyses were carried out with SPSS package
version 20.0 (Statistical Product and Service Solutions,
Chicago, IL, USA). Data of multiple tissue blocks from
the same patient were averaged to finally represent each
case with 1 value per ROI. Normal distribution of the data
was tested using the Shapiro-Wilk procedure. When data
were normally distributed, differences between control
subjects, MS patients without hippocampal lesions, MS
patients with active/chronic active hippocampal lesions
and MS patients with inactive hippocampal lesions were
compared using one-way ANOVA, followed by Tukey’s
post hoc analysis. When data were not normally distrib-
uted, a Kruskal-Wallis test was performed followed by a
Mann-Whitney U post-hoc analysis.
Differences in CCL2 and CCR2 immunoreactivity
within subject WM vs GM were analyzed for controls,
MS patients without and with hippocampal demyelination
using the Wilcoxon Signed Rank Test. The Wilcoxon
Signed Rank Test was also used for analyzing the differ-
ence between the number of CCL2 and CCR2 expressing
cells within subject lesion center versus lesion border of
MS patients with hippocampal demyelination. For evaluat-
ing the response of WM and GM astrocytes to bz-ATP, a
2-way ANOVA was performed followed by a Student’s t-
test (Bonferroni adjusted). Proliferation of microglia was
analyzed using a one-way ANOVA, followed by LSD post
hoc analysis. P-values < 0.05 were considered significant.
Results
Lesion characterization
Areas of hippocampal demyelination were identified by
loss of MBP immunoreactivity (Figure 1A, F). No demye-
lination was observed in the sections of non-neurological
control subjects (not shown). Of the 18 MS patients, 6 did
not show demyelination in the hippocampal tissue block
obtained. The other 12 MS patients showed demyelinatedareas in hippocampal tissue blocks studied, which were
subsequently examined for the presence of MHC-II posi-
tive cells to determine the lesion activity. Of these, 5 were
classified as having active/chronic active lesions. Together,
these 5 patients had 11 lesions, of which 6 mixed WM/
GM lesions, 1 purely GM lesion, and 4 purely WM le-
sions. Seven MS patients were classified as having inactive
lesions. In total, this group comprised 22 lesions, of which
12 mixed WM/GM lesions, 6 purely GM lesions, and 4
purely WM lesions. In agreement with previous studies
[9,50], only a minimal number of CD3 positive T-cells was
observed in active WM lesions, whereas these cells were
absent in active GM lesions (data not shown).
CCL2 and CCR2 mRNA in human hippocampus
Levels of CCL2 and CCR2 mRNA within the hippocampus
of MS patients and control subjects were determined by
qPCR. While CCL2 and CCR2 mRNA in myelinated MS
hippocampi (n = 5) was not altered compared to control
hippocampi (n = 5), a ~4 fold increase in CCL2 mRNA
(ANOVA; F = 18.07; p < 0.001) and a ~3 fold increase in
CCR2 mRNA (ANOVA, F = 5.63; p = 0.02) was measured
in demyelinated hippocampi (n = 5) compared to myelin-
ated MS hippocampi (p < 0.001; p = 0.03, respectively)
and compared to control hippocampi (p < 0.001; p = 0.04,
respectively) (Figure 2A, B).
Semi-quantitative analysis of CCL2 and CCR2 positive cells
For semi-quantitative analysis CCL2 and CCR2 positive
cells were counted in several ROIs (see Material and
methods). When more tissue blocks of one patient were
available, scores for the same ROI in different tissue
blocks were averaged. For each group, i.e. control subjects,
MS patients without hippocampal lesions, MS patients
with active/chronic active hippocampal lesions and MS
patients with inactive hippocampal lesions, the mean
and standard deviation of CCL2 and CCR2 positive cell
numbers per ROI per case are summarized in Table 5.
CCL2
In hippocampal WM of control subjects and in WM of
myelinated hippocampi of MS patients a few CCL2 posi-
tive cells were found upon immunohistochemical analysis
(Figure 3A, D). However, at the border of active demye-
linated WML an increase in CCL2 positive cells was
observed (45.3 ± 21.7 cells/mm2; Figure 3E), which was
significantly different from the hippocampal WM of
control subjects (6.6 ± 9.1 cells/mm2) and WM of mye-
linated hippocampi of MS patients (8.4 ± 11.6 cells/mm2)
(Kruskall-Wallis, p = 0.031; Mann Whitney U, p = 0.004
and p = 0.017, respectively) (Figure 3M). CCL2 positive
cells were found within the center of active WML (21.1 ±
20.2 cells/mm2) (Figure 3B), albeit to a lesser extent, as well
as in the center (Figure 3C) and at the border (Figure 3 F)
Figure 2 Semi-quantitative RT-PCR analysis of CCL2 and CCR2
mRNA. qPCR of CCL2 (A) and CCR2 (B) mRNA in the hippocampus
of control subjects, MS patients without hippocampal lesions and
MS patients with hippocampal lesions. Data represent mean ± S.E.M.
(n = 5) and are expressed relative to GAPDH.
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scarce CCL2 immunoreactivity was observed, irrespective
of the absence or presence of GML (Figure 3G-L).
When we compared CCL2 immunoreactivity in WM and
GM of control subjects, MS patients without hippocampal
lesions and MS patients with active or inactive lesions,
we found significantly more CCL2 positive cells in hip-
pocampal WM (6.6 ± 9.1 cells/mm2) than GM (1.0 ± 2.9
cells/mm2) of control subjects (Wilcoxon Signed Rank test,
p = 0.04). Moreover, in the center of active WML more
CCL2 positive cells (21.1 ± 20.2 cells/mm2) were found
than in the center of active GML (0.1 ± 0.3 cells/mm2)
(Wilcoxon Signed Rank test, p = 0.04). CCL2 immuno-
reactive cells within the WM border of inactive lesions
(16.1 ± 23.8 cells/mm2) were significantly outnumbering
those found within the hippocampal GM border of inactive
lesions (1.8 ± 3.3 cells/mm2) (Wilcoxon Signed Rank
test, p = 0.04) (Figure 3M).
Finally, the number of CCL2 positive cells was signifi-
cantly higher within the WM border compared to the
center of active WM hippocampal lesions (Wilcoxon
Signed Rank test, p = 0.04) (Figure 3M).
CCR2
CCR2 positive cells were found infrequently within the
WM of control subjects and myelinated MS hippocampiTable 5 Mean CCL2+ and CCR2+ cell numbers
Group Location Number of CCL2+ cells (mean ± S
WM GM
Control (n = 9) Na 6.6 ± 9.1 1.0 ±
NDH (n = 6) Na 8.4 ± 11.6 0 ± 0
Inactive lesions (n = 7) Center 8.2 ± 9.7 0.7 ±
Border 16.1 ± 23.8 1.8 ±
Active lesions (n = 5) Center 21.1 ± 20.2 0.1 ±
Border 45.3 ± 21.7 0 ± 0
Na = Not applicable; NDH = Non-demyelinated hippocampi; SD = Standard deviation(Figure 4A, D). However, within the center (Figure 4B)
and at the border (Figure 4E) of active demyelinated
WML, CCR2 positive cells were abundantly present. In
inactive WML, CCR2 expression was still present but to
a lesser extent within the center (Figure 4C) and at the
border (Figure 4F) of the lesion. Semi-quantification in-
dicated that inactive hippocampal WML presented with
significantly more CCR2 positive cells within the border
(58.0 ± 84.8 cells/mm2) compared to hippocampal WM of
control subjects (5.0 ± 7.5 cells/mm2) (ANOVA, F = 19.77,
p < 0.001; Tukey HSD, p = 0.008). Active hippocampal
WML showed significantly more CCR2 immunopositive
in the WM border (256.6 ± 90.2 cells/mm2) compared to
WM in control hippocampi, and WM in myelinated MS
hippocampi (9.1 ± 8.5 cells/mm2) and the WML and
border of inactive hippocampal lesions (ANOVA, F = 19.77,
p < 0.001; Tukey HSD, p < 0.005 for all comparisons). Simi-
larly, the center of active WML (189.8 ± 152.6 cells/mm2)
showed significantly more CCR2 positive cells than WM in
control hippocampi, WM in myelinated MS hippocampi
and the center of inactive WML (20.1 ± 25.2 cells/mm2)
(Kruskal-Wallis, p = 0.003; Mann-Whitney U, p = 0.001,
p = 0.004 and p = 0.003, respectively).
In contrast to the absence of CCR2 positive cells in
hippocampal GM of control subjects and in GM of mye-
linated hippocampal tissue of MS patients (Figure 4G, J),
CCR2 immunoreactive cells appeared within the center
and at the border of active GML (Figure 4H, K). Less CCR2
positive cells were found in inactive GML (Figure 4I, L).
After semi-quantification we measured a significant
increase in CCR2 immunoreactivity within the hippo-
campal GML center (21.8 ± 21.4 cells/mm2) and border
(63.3 ± 14.3 cells/mm2) of active lesions compared to hippo-
campal GM of control subjects (1.9 ± 1.9 cells/mm2), GM
of myelinated hippocampi of MS patients (1.1 ± 2.6 cells/
mm2) and GML center (1.4 ± 2.4 cells/mm2) and border
(2.3 ± 3.9 cells/mm2) of inactive lesions (Kruskal-Wallis,
p = 0.01; Mann-Whitney U, p = 0.01, p = 0.009 and p = 0.01,
respectively; Kruskal-Wallis, p = 0.007; Mann-Whitney U,
p < 0.003; p = 0.01 and p = 0.006, respectively) (Figure 4M).
When we compared CCR2 immunoreactivity in WM
and GM of control subjects, MS patients without hippo-D) per mm2 Number of CCR2+ cells (mean ± SD) per mm2
WM GM
2.9 5.0 ± 7.5 1.9 ± 1.9
9.1 ± 8.5 1.1 ± 2.6
1.9 20.1 ± 25.2 1.4 ± 2.4
3.3 58.0 ± 84.8 2.3 ± 3.9
0.3 189.8 ± 152.6 21.8 ± 21.4
256.6 ± 90.2 63.3 ± 14.3
.
Figure 3 Semi-quantitative analysis of CCL2 positive cell numbers. CCL2 positive cells were only sporadically found within the hippocampal
WM of control subjects (A) and MS patients without hippocampal lesions (D). The number of CCL2 positive cells was slightly increased within the
WM centre of active (B) and inactive (C) lesions and borders (F). A significant increase in the number of CCL2 positive cells was found within the WM
border of active lesions (E). CCL2 positive cells were barely detected within the hippocampal GM of control subjects (G), MS patients without
hippocampal lesions (J), the lesion centre (H) and border (K) of active lesions and only sporadically within the lesion centre (I) and border (L) of
inactive lesions. Semi-quantification of CCL2 positive cells (M). Scale bar (A-L) = 60 μm; + p < 0.05 versus cell number in WM of non-demyelinated
hippocampi of MS patients and in hippocampal WM of control subjects; # p < 0.05.
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Figure 4 CCR2 immunoreactivity. Low numbers of CCR2 positive cells were observed within the hippocampal WM of control subjects (A), MS
patients without hippocampal lesions (D), the lesion centre (C) and border (F) of inactive lesions. A significant increase in the number of CCR2
positive cells was found within the WM centre (B) and border (E) of active lesions. CCR2 positive cells were barely detected within the hippocampal GM
of control subjects (G) and MS patients without hippocampal lesions (J). The number of CCR2 positive cells was slightly increased within the WM centre
of active (H) and inactive (I) lesions and borders (L). A significant increase in the number of CCR2 positive cells was found within the GM border of active
lesions (K). Semi-quantification of CCR2 positive cells (M). Scale bar (A-L) = 60 μm. + p < 0.01 compared to number in the WM of control subjects and
the WM border of active lesions, ++ p < 0.01 compared to number in the GM of control subject and the GM border of inactive lesions and +++ p < 0.01
compared to number in the WM border of inactive lesions and WM of non-demyelinated hippocampi of MS patients and control subjects. * p < 0.05
compared to numbers in the GM center of inactive lesions and GM of MS patients without hippocampal lesions and control subjects, and ** p < 0.01
compared to numbers in the WM center of inactive lesions and WM of MS patients without hippocampal lesions and control subjects. ; # p <0.05.
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lesions we found that the number of CCR2 positive cells
was significantly higher in hippocampal WM compared
to GM of MS patients without hippocampal lesions
(Wilcoxon Signed Rank test, p = 0.03). In addition, CCR2
positive cells were significantly more numerous in the
WML center compared to the GML center of active and
inactive hippocampal lesions (Wilcoxon Signed Rank
test, p = 0.04 and p = 0.05, respectively). Furthermore,
the number of CCR2 positive cells was significantly
higher within the WML border compared to GML border
of hippocampal inactive lesions (Wilcoxon Signed Rank
test, p = 0.02) (Figure 4M).
Cellular identification of CCL2 and CCR2 immunoreactivity
Based on the morphological appearance of CCL2 and
CCR2 positive cells in hippocampal MS lesions, we per-
formed double labeling studies on lesioned hippocampal
material to determine whether CCL2 is expressed by astro-
cytes and CCR2 by microglia. The experiments revealed
extensive co-localization of CCL2 with GFAP in all lesion
types (Figure 5A-C), demonstrating that astrocytes indeed
expressed CCL2. Additionally, CCR2 co-localized with
iba-1 positive ramified microglia in WML and GML
(Figure 5D-F), and with infiltrating monocytes/macro-
phages or amoeboid microglia in WML (Figure 5G-I).
Primary culture of astrocytes and microglia
Bz-ATP-induced CCL2 mRNA expression by WM- and GM-
derived astrocytes
The observed outnumbering of CCL2 positive cells in
active WML compared to active GML was verified by an
in vitro study. Upon stimulation with a disease-relevant
stimulus, i.e. bz-ATP, primary rat WM astrocytes, showed
a significant 6-fold increase in CCL2 mRNA compared to
vehicle-treated (medium) astrocytes (p = 0.034). In con-
trast, GM-derived astrocytes showed a minimal increase
in CCL2 mRNA upon bz-ATP stimulation (Figure 6A).
CCR2 mediated proliferation of GM-derived microglia
The relative absence of CCL2 production by GM astro-
cytes in vivo and in vitro urged the question whether the
clearly present CCR2 in GM microglia is bound andactivated by CCL2 and results in a functional response.
Therefore, primary cortical rat microglia were treated
with CCL2 in the absence or presence of the selective
CCR2 antagonist INCB3344. Incubation of the microglia
with INCB3344 only did not affect microglial prolifera-
tion. Upon CCL2 treatment, the proliferation of microglia
was significantly increased (LSD, p = 0.04). In the presence
of INCB3344, this CCL2-mediated increase in microglial
proliferation was eliminated (Figure 6B). In support of a
role for CCR2 in cell proliferation in GM of MS patients,
we observed BM28 positive/CCR2 positive microglial cells
in hippocampal GML (Figure 6C).
Discussion
The present study demonstrates that CCL2 in astrocytes
and its receptor CCR2 in monocytes/macrophages and
microglia are significantly upregulated at the mRNA and
protein level in hippocampal lesions of MS patients.
Moreover, we show for the first time that there is a spatial
and quantitative discrepancy in the distribution of CCL2
and CCR2 in the hippocampus. CCL2 and CCR2 appear
in hippocampal WML whereas in GML only CCR2 is
present, and more CCL2 and CCR2 positive cells are
present in hippocampal WM compared to hippocampal
GM. This discrepancy can contribute to the pathological
differences observed in WML versus GML of MS patients
and may possibly affect subsequent disease outcome.
Accumulating evidence shows that within the CNS of
MS patients besides WML also GML, e.g. hippocampal
lesions [8,9], are present which may explain functional
deficits seen in MS patients [51,52]. Moreover, GML
correlate better with various clinical parameters than
WML [53-55]. It is therefore of utmost interest to
understand the pathological features of GML versus WML,
because that may give direction to the identification of
novel therapeutic targets. An important pathological
feature of WML is the infiltration of immune cells through
the blood-brain barrier (BBB) into the CNS, which is
considered to play a crucial role in the pathophysiology of
MS [15-17]. In contrast, immunohistochemical studies
indicate that the GM is not, or far less, affected by infil-
trating immune cells [20]. Therefore, we hypothesized
that an important mediator of immune cell infiltration,
Figure 6 CCL2 mRNA in astrocytes and CCL2 induced microglial proliferation. Primary WM rat astrocytes produce significantly more CCL2
mRNA upon treatment with bz-ATP than GM astrocytes (A). Primary rat microglia significantly increased their proliferation rate upon treatment
with CCL2. This effect was abolished when the cells were co-incubated with a CCR2 antagonist (B). Immunofluorescent double labelling study
showed colocalization between BM28 and CCR2 in post mortem human hippocampal GML (C). * p < 0,05.
Figure 5 Cellular localization of CCL2 positive and CCR2 positive cells. Representative images of confocal laser scanning microscopy
revealed colocalization of CCL2 with GFAP (A-C), whereas CCR2 colocalized with ramified iba-1 positive cells in hippocampal GM (D-F), and
amoeboid iba-1 positive cells in hippocampal WM (G-I). Scale bar (A-F) = 10 μm.
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a lesser extent in affected GM regions in the hippocampus
of MS patients.
Our observation that astrocytes are the source of
CCL2 is in agreement with previous studies showing
CCL2 expression by cells with an astrocytic morphology
[36,56]. In line with the observation that CCL2 is more
abundantly present in WM/WML is that WM-derived
astrocytes produce significantly more CCL2 upon stimula-
tion with bz-ATP in vitro, whereas GM-derived astrocytes
hardly respond. This is not due to a total irresponsive-
ness of GM-derived astrocytes, since stimulation with
pro-inflammatory cytokines interleukin-1β and tumor
necrosis factor-α resulted in a strong increase in CCL2
mRNA expression (data not shown). Moreover, the low
responsiveness to bz-ATP cannot be attributed to an
absence of the P2X7 receptor for ATP on GM astrocytes,
since we observed P2X7 receptor immunoreactivity in and
on WM- and GM-derived astrocytes (data not shown).
Still, it cannot be excluded that the observed difference
in bz-ATP-mediated CCL2 production by WM- versus
GM-derived astrocytes is due to variation in expression
of purinergic receptors other than P2X7, though thus
far no such heterogeneity between WM and GM astro-
cytes has been described [57]. The observed discrepancy
in the number of CCL2 positive cells in hippocampal
WM/WML versus GM/GML is in line with the observa-
tion that CCL2 mRNA levels are significantly higher
within the corpus callosum (WM) compared to the cortex
(GM) in both control mice as well as a mouse model for
MS, e.g. cuprizone treated mice [58]. These differences
in CCL2 expression by WM versus GM astrocytes
might be explained by regionally dependent differences
in astrocytes. Indeed, two different types of astrocytes
have been recognized, i.e. fibrous astrocytes that reside
mainly in the WM and protoplasmic astrocytes that are
preferentially located in the GM [59]. The heterogeneity
between fibrous and protoplasmic astrocytes is not re-
stricted to morphology. Molecular differences between
fibrous and protoplasmic astrocytes have been described
as well (reviewed in [60]) with WM-derived astrocytes
expressing more e.g. GFAP and glutamate transporter-1
(GLT-1) [61]. Such differences between astrocytes in
WML versus GML as observed in the present study by
heterogeneity in CCL2 expression and production can
contribute to the variety in pathological and functional
outcome of WML and GML.
An alternative explanation for the observed difference
between CCL2 positive cell number in hippocampal WM
vs hippocampal GM can be the local variation in presence
of pro-inflammatory cytokines, e.g interleukin (IL)-1β.
These cytokines increase CCL2 production by astrocytes
in vitro [62] and could thus, besides ATP, contribute to
the CCL2 producing astrocytes found in WML. Indeed, inWML of MS patients, IL-1β positive cells are present [63],
but have thus far never been studied in GML. In rats
suffering from relapsing EAE, IL-1β appears in certain
GM areas, but no IL-1β was observed in the hippocampus
of these animals [64], and this absence of IL-1β could
contribute to the lack of CCL2 in GML. Since neurons
located within the GM are known to suppress the pro-
duction of pro-inflammatory factors [65-67], this could
also indirectly prevent CCL2 production. Thus, astrocyte-
specific and environmental conditions can explain the
relative lack of CCL2 in GML. Since astrocyte-derived
CCL2 is a prominent factor involved in the attraction of
leukocytes through the BBB in WML in MS [25,26], the
relative absence of CCL2 in GML may subsequently explain
the lack of infiltrating immune cells in this type of lesion.
Additionally, CCL2 has been described to interact with
endothelial cells [68] consequently disrupting the BBB.
Thus, the absence of CCL2 in the hippocampal GML
could explain a lack of BBB damage in GML [69].
The present immunohistochemical study showed that
CCR2 is observed in hippocampal WML as well as GML
in myeloid-like cells. Moreover, CCR2 was significantly
more expressed in hippocampal WML than in GML.
Interestingly, fluorescent double-labelling of CCR2 and
Iba1 indicated that in hippocampal WML CCR2 is
expressed mainly by infiltrating monocytes/macrophages
and amoeboid microglia, while in the GML CCR2 is
expressed mainly by ramified microglia, which is in line
with studies showing CCR2 expression by microglia and
macrophages in vitro and ex vivo, which, however, did
not differentiate between their regional origin [70-72].
This suggests that during MS lesion formation, the source
of CCR2 positive cells in WML are both resident micro-
glia and infiltrating monocytes/macrophages, while in the
GML CCR2 positive cells are mainly resident microglia.
Like our data for CCL2, the discrepancy between the
higher number of CCR2 positive cells in hippocampal
WM versus lower number in hippocampal GM might be
explained by differences that reside within WM and GM,
e.g. the WM harbors more microglia [73], which are more
prone to be pro-inflammatory [74,75].
Another interesting finding is that we observed that
CCL2 and CCR2 positive cells are more numerous in
the border of the lesion with ongoing demyelinating
activity and less in the demyelinated center of the lesion,
irrespective of WML or GML. Indeed, in WML it has
already been shown that CCL2 and CCR2 are mainly
present at the border [35,36], whereas it was unknown
for GML. Moreover, the present study showed that
CCL2 and CCR2 immunoreactivity in the hippocampus
was significantly less when either WML or GML were
inactive. This has only been reported for CCL2 in WML
[56]. Its receptor CCR2 has been shown to be mostly
expressed during active inflammation and demyelination
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that CCL2 expression by astrocytes plays an important
role during the active phase of disease, and that CCL2-
CCR2 interaction in this way likely contributes to infiltra-
tion of immune cells occurring during active WML
formation in MS.
Although CCL2 was hardly observed in GML, its recep-
tor CCR2 was upregulated in both active WML and GML.
We questioned whether the CCR2 receptor expressed
by microglia in GM can act as a functional receptor. To
this end we studied CCL2-mediated GM microglial pro-
liferation in vitro. Indeed, CCL2 induced a significant
increase in the percentage of proliferating GM microglial
cells, which was prevented by co-incubation with the
specific CCR2 antagonist INCB3344. This indicates that
GM-derived microglia express a functional CCR2 recep-
tor, and thus CCL2-CCR2 mediated effects can occur in
GML, e.g. the induction of microglial proliferation [30].
This was supported by our observation that CCR2 is
expressed by BM28 positive proliferating microglia.
Their localization at the border of GML suggests that
the proliferating microglial cells are either a consequence
of or contribute to GML formation. A recent study indi-
cated that proliferating parenchymal microglia are the
main source of microgliosis after ischaemic stroke [76].
However, the role of microglial proliferation during
demyelination remains to be established. Since only nano-
molar concentrations of CCL2 are needed to activate
CCR2 [77], it is possible that, although no evident
appearance of CCL2 positive cells in the GM was observed,
increased presence of the CCR2 receptor increases the
chance of CCL2-CCR2 interaction, and thus minute
amounts of CCL2 can result in CCR2 mediated responses
e.g. microglia proliferation in GML. Alternatively, it is
even more likely that CCL2 diffuses from neighbouring
WML into the GML to exert its effect. We can, however,
not exclude the possibility that other chemokines, i.e.
CCL8 or CCL16, known to be ligands for CCR2, interact
with the receptor to induce in vivo effects, e.g. cell
migration or proliferation, but no expression of these
chemokines in MS GML has been described.
Overall, we conclude that the difference in CCL2 and
CCR2 expression in hippocampal WML versus GML of
MS patients, at least partly, explains the pathological
differences observed in WML and GML. As such CCL2-
CCR2 interaction is likely to be involved in leukocyte
migration into the CNS contributing to WML formation,
whereas the relative absence of CCL2 in GML of MS
patients may explain the lack of infiltrating immune cells
in this type of lesion. Based on our in vitro experiments,
we propose that the CCR2 receptor in GM is a functional
receptor and is involved in resident microglial cell pro-
liferation, thereby contributing to microgliosis. Further-
more, the discrepancy in CCL2 and CCR2 expression inhippocampal WML and GML implies that the patho-
genesis of WML formation differs from that of GML.
As such, our data support several lines of evidence
which already pointed towards a possible difference in
the pathways underlying demyelination in WM and GM,
as there is no, or only low, correlation between the extent
of demyelination in WM and GM [6,11]. Although under
debate, WML formation is considered to start with peri-
vascular infiltration of CD4+ and CD8+ T-cells [16,78-81],
whereas GML formation has been suggested to be initi-
ated by meningeal inflammation [82,83]. Although this
may hold true for GM cortical lesions in MS, this does
not necessarily explain the occurrence of subcortical
GML, e.g. hippocampal lesions. With our observations on
the discrepancy in CCL2 and CCR2 expression in WML
and GML we have added an additional factor that may
explain or contribute to the pathways underlying WML
and GML formation in MS.
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